Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Conivaptan Hydrochloride

FDA-approved product (injectable, intravenous), marketed as Vaprisol, Vaprisol In 5% Dextrose In Plastic Container.

Registered studies
21
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Conivaptan Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Vasopressin antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

21registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Conivaptan Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Conivaptan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

    NCT03000283 · start 2017-03-22

    Registered record
    Registry ID
    NCT03000283
    Conditions
    Cerebral Hemorrhage; Cerebral Edema; Intracerebral Hemorrhage; Stroke
    Interventions
    Conivaptan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-03-22
    Completion
    2019-04-15
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Hemorrhage; Cerebral Edema; Intracerebral Hemorrhage; Stroke
    InterventionConivaptan
    PhasePhase 1
    Registry statusCompleted

  • Study of Stroke Related Edema Treatments

    NCT01954290 · start 2015-09

    Registered record
    Registry ID
    NCT01954290
    Conditions
    Acute Cerebrovascular Accident; Cerebral Edema
    Interventions
    Conivaptan; Hypertonic saline; Mannitol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-09
    Completion
    2015-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Cerebrovascular Accident; Cerebral Edema
    InterventionConivaptan; Hypertonic saline; Mannitol
    PhasePhase 2
    Registry statusWithdrawn

  • Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients

    NCT01752543 · start 2013-12

    Registered record
    Registry ID
    NCT01752543
    Conditions
    Heart Failure
    Interventions
    Conivaptan; Placebo (Dextrose)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-12
    Completion
    2015-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionConivaptan; Placebo (Dextrose)
    PhasePhase 4
    Registry statusCompleted

  • A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia

    NCT01451411 · start 2012-02

    Registered record
    Registry ID
    NCT01451411
    Conditions
    Hyponatremia
    Interventions
    Conivaptan hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-02
    Completion
    2014-01
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyponatremia
    InterventionConivaptan hydrochloride; Placebo
    PhasePhase 3
    Registry statusTerminated

  • A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

    NCT01370148 · start 2011-04

    Registered record
    Registry ID
    NCT01370148
    Conditions
    Liver Disease
    Interventions
    conivaptan hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04
    Completion
    2014-02
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Disease
    Interventionconivaptan hydrochloride
    PhasePhase 1
    Registry statusCompleted

  • Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury

    NCT00930202 · start 2009-08

    Registered record
    Registry ID
    NCT00930202
    Conditions
    Severe Traumatic Brain Injury
    Interventions
    Conivaptan (Vaprisol)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-08
    Completion
    2010-06
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Traumatic Brain Injury
    InterventionConivaptan (Vaprisol)
    PhasePhase 1
    Registry statusCompleted

  • Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure

    NCT00924014 · start 2009-07

    Registered record
    Registry ID
    NCT00924014
    Conditions
    Heart Failure
    Interventions
    Conivaptan; Furosemide; Conivaptan and furosemide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2009-07
    Completion
    2010-03
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionConivaptan; Furosemide; Conivaptan and furosemide
    PhaseNot applicable
    Registry statusUnknown

  • Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)

    NCT00843986 · start 2009-04

    Registered record
    Registry ID
    NCT00843986
    Conditions
    Hyponatremia; Acute Decompensated Heart Failure
    Interventions
    conivaptan; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2009-04
    Completion
    2009-08
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyponatremia; Acute Decompensated Heart Failure
    Interventionconivaptan; placebo
    PhasePhase 3
    Registry statusTerminated

  • Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

    NCT00887627 · start 2009-04

    Registered record
    Registry ID
    NCT00887627
    Conditions
    Kidney Diseases; Hyponatremia
    Interventions
    conivaptan hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-04
    Completion
    2010-07
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Diseases; Hyponatremia
    Interventionconivaptan hydrochloride
    PhasePhase 1
    Registry statusCompleted

  • Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

    NCT00851227 · start 2009-02

    Registered record
    Registry ID
    NCT00851227
    Conditions
    Liver Disease; Hyponatremia
    Interventions
    conivaptan hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-02
    Completion
    2010-01
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Disease; Hyponatremia
    Interventionconivaptan hydrochloride
    PhasePhase 1
    Registry statusCompleted

  • Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure

    NCT00811486 · start 2009-01

    Registered record
    Registry ID
    NCT00811486
    Conditions
    Right Heart Failure; Pulmonary Hypertension
    Interventions
    Spironolactone and conivaptan
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2009-01
    Completion
    2010-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRight Heart Failure; Pulmonary Hypertension
    InterventionSpironolactone and conivaptan
    PhaseNot applicable
    Registry statusWithdrawn

  • Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion

    NCT00806910 · start 2008-10

    Registered record
    Registry ID
    NCT00806910
    Conditions
    Heart Failure
    Interventions
    Conivaptan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-10
    Completion
    2010-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionConivaptan; Placebo
    PhasePhase 4
    Registry statusWithdrawn

  • Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients

    NCT00727090 · start 2008-08

    Registered record
    Registry ID
    NCT00727090
    Conditions
    Hyponatremia
    Interventions
    Conivaptan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2008-08
    Completion
    2010-02
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyponatremia
    InterventionConivaptan
    PhasePhase 4
    Registry statusTerminated

  • Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients

    NCT00684164 · start 2008-05

    Registered record
    Registry ID
    NCT00684164
    Conditions
    Hyponatremia
    Interventions
    Conivaptan; D5
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2008-05
    Completion
    2010-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyponatremia
    InterventionConivaptan; D5
    PhasePhase 3
    Registry statusWithdrawn

  • A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients

    NCT00592475 · start 2007-12

    Registered record
    Registry ID
    NCT00592475
    Conditions
    Liver Cirrhosis
    Interventions
    conivaptan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-12
    Completion
    2008-11
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis
    Interventionconivaptan; Placebo
    PhasePhase 2
    Registry statusCompleted